Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$9.6 million.

  • Corvus Pharmaceuticals' Free Cash Flow fell 51.34% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year decrease of 45.62%. This contributed to the annual value of -$25.4 million for FY2024, which is 6.07% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Free Cash Flow stood at -$9.6 million for Q3 2025, which was down 62.41% from -$5.9 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Free Cash Flow registered a high of -$5.2 million during Q1 2024, and its lowest value of -$9.6 million during Q3 2025.
  • In the last 3 years, Corvus Pharmaceuticals' Free Cash Flow had a median value of -$5.9 million in 2025 and averaged -$6.6 million.
  • Data for Corvus Pharmaceuticals' Free Cash Flow shows a peak YoY increase of 36.69% (in 2024) and a maximum YoY decrease of 63.83% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Free Cash Flow stood at -$7.5 million in 2022, then surged by 31.54% to -$5.2 million in 2023, then slumped by 63.83% to -$8.5 million in 2024, then slumped by 51.34% to -$9.6 million in 2025.
  • Its Free Cash Flow stands at -$9.6 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$8.3 million for Q1 2025.